Perković Dijana, Petrić Marin, Maleš Maja, Erceg Maleš Ivana, Radić Mislav
Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, University Hospital of Split, 21000 Split, Croatia.
Department of Internal Medicine, School of Medicine, University of Split, 21000 Split, Croatia.
Curr Issues Mol Biol. 2025 Feb 22;47(3):142. doi: 10.3390/cimb47030142.
There are many explanations for increased levels of serum uric acid (SUA) in patients with psoriatic arthritis (PsA), but correlation with different treatment options in PsA is not well elucidated. Our aim was to determine the effects of biological disease-modifying antirheumatic drugs (bDMARDs) on SUA levels in patients with PsA.
We analyzed the data of PsA patients treated with different bDMARDs from January 2007 to June 2021. Patients treated with interleukin-17 (IL-17) inhibitors (secukinumab and ixekizumab) and tumor necrosis factor α (TNFα) inhibitors (golimumab, infliximab, adalimumab, certolizumab pegol, and etanercept) were included.
A total of 87 patients were included. The SUA levels decreased in 60 (69%) patients after a 3-6-month-long follow-up, and in 25 (28.7%), we noticed an increase. The average decrease in SUA levels was 9.4 ± 49.5 µmol/L ( = 0.039); for TNFα patients, it was 7.3 ± 59.8 µmol/L ( = 0.386), and for IL-17 patients, it was 12.6 ± 28.4 µmol/L ( = 0.013). The levels of SUA decreased in 81.8% of patients treated with infliximab, as well as in 76% of those treated with secukinumab and in 72.7% of those treated with etanercept. The largest average decrease in SUA levels was recorded in the group treated with golimumab (23 µmol/L).
A significant decrease in SUA levels was noticed, especially in patients treated with IL-17 inhibitors. Further studies should identify which bDMARD is the most potent in the lowering of SUA levels. bDMARDs were efficient in PsA disease activity.
对于银屑病关节炎（PsA）患者血清尿酸（SUA）水平升高有多种解释，但PsA中不同治疗方案与之的相关性尚未得到充分阐明。我们的目的是确定生物性改善病情抗风湿药物（bDMARDs）对PsA患者SUA水平的影响。
我们分析了2007年1月至2021年6月接受不同bDMARDs治疗的PsA患者的数据。纳入了接受白细胞介素-17（IL-17）抑制剂（司库奇尤单抗和依奇珠单抗）和肿瘤坏死因子α（TNFα）抑制剂（戈利木单抗、英夫利昔单抗、阿达木单抗、赛妥珠单抗和依那西普）治疗的患者。
共纳入87例患者。经过3至6个月的随访，60例（69%）患者的SUA水平下降，25例（28.7%）患者的SUA水平升高。SUA水平的平均下降值为9.4±49.5µmol/L（P=0.039）；TNFα抑制剂治疗的患者为7.3±59.8µmol/L（P=0.386），IL-17抑制剂治疗的患者为12.6±28.4µmol/L（P=0.013）。接受英夫利昔单抗治疗的患者中有81.8%的SUA水平下降，接受司库奇尤单抗治疗的患者中有76%，接受依那西普治疗的患者中有72.7%。SUA水平平均下降幅度最大的是接受戈利木单抗治疗的组（23µmol/L）。
观察到SUA水平显著下降，尤其是接受IL-17抑制剂治疗的患者。进一步的研究应确定哪种bDMARD在降低SUA水平方面最有效。bDMARDs对PsA疾病活动有效。
